These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 7508268)

  • 21. New coupling reagents for the preparation of disulfide cross-linked conjugates with increased stability.
    Arpicco S; Dosio F; Brusa P; Crosasso P; Cattel L
    Bioconjug Chem; 1997; 8(3):327-37. PubMed ID: 9177838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugates.
    Svensson HP; Vrudhula VM; Emswiler JE; MacMaster JF; Cosand WL; Senter PD; Wallace PM
    Cancer Res; 1995 Jun; 55(11):2357-65. PubMed ID: 7757987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity.
    Dubowchik GM; Firestone RA; Padilla L; Willner D; Hofstead SJ; Mosure K; Knipe JO; Lasch SJ; Trail PA
    Bioconjug Chem; 2002; 13(4):855-69. PubMed ID: 12121142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains.
    King HD; Dubowchik GM; Mastalerz H; Willner D; Hofstead SJ; Firestone RA; Lasch SJ; Trail PA
    J Med Chem; 2002 Sep; 45(19):4336-43. PubMed ID: 12213074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dipeptide-based highly potent doxorubicin antibody conjugates.
    Jeffrey SC; Nguyen MT; Andreyka JB; Meyer DL; Doronina SO; Senter PD
    Bioorg Med Chem Lett; 2006 Jan; 16(2):358-62. PubMed ID: 16275070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody conjugates with morpholinodoxorubicin and acid-cleavable linkers.
    Mueller BM; Wrasidlo WA; Reisfeld RA
    Bioconjug Chem; 1990; 1(5):325-30. PubMed ID: 1711377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates.
    Trail PA; Willner D; Lasch SJ; Henderson AJ; Hofstead S; Casazza AM; Firestone RA; Hellström I; Hellström KE
    Science; 1993 Jul; 261(5118):212-5. PubMed ID: 8327892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A carbohydrate-directed heterobifunctional cross-linking reagent for the synthesis of immunoconjugates.
    Zara JJ; Wood RD; Boon P; Kim CH; Pomato N; Bredehorst R; Vogel CW
    Anal Biochem; 1991 Apr; 194(1):156-62. PubMed ID: 1867379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytotoxicity of chimeric (human-murine) monoclonal antibody BR96 IgG, F(ab')2, and Fab' conjugated to Pseudomonas exotoxin.
    Siegall CB; Gawlak SL; Chin JJ; Zoeckler ME; Kadow KF; Brown JP; Braslawsky GR
    Bioconjug Chem; 1992; 3(4):302-7. PubMed ID: 1390985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor activity of adriamycin (hydrazone-linked) immunoconjugates compared with free adriamycin and specificity of tumor cell killing.
    Braslawsky GR; Edson MA; Pearce W; Kaneko T; Greenfield RS
    Cancer Res; 1990 Oct; 50(20):6608-14. PubMed ID: 2208123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determination of immunoreactivity of doxorubicin antibody immunoconjugates by a Le(y) competitive RIA.
    Zhao H; Willner D; Cleaveland JS; Braslawsky GR; Brown JP
    Bioconjug Chem; 1992; 3(6):549-53. PubMed ID: 1361153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced stability in vitro and in vivo of immunoconjugates prepared with 5-methyl-2-iminothiolane.
    Carroll SF; Bernhard SL; Goff DA; Bauer RJ; Leach W; Kung AH
    Bioconjug Chem; 1994; 5(3):248-56. PubMed ID: 7918744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting Triple Negative Breast Cancer Cells with Novel Cytotoxic Peptide-Doxorubicin Conjugates.
    Ziaei E; Saghaeidehkordi A; Dill C; Maslennikov I; Chen S; Kaur K
    Bioconjug Chem; 2019 Dec; 30(12):3098-3106. PubMed ID: 31715102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polymer conjugates of doxorubicin bound through an amide and hydrazone bond: Impact of the carrier structure onto synergistic action in the treatment of solid tumours.
    Etrych T; Subr V; Laga R; Ríhová B; Ulbrich K
    Eur J Pharm Sci; 2014 Jul; 58():1-12. PubMed ID: 24632485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced tumor cell selectivity of adriamycin-monoclonal antibody conjugate via a poly(ethylene glycol)-based cleavable linker.
    Suzawa T; Nagamura S; Saito H; Ohta S; Hanai N; Kanazawa J; Okabe M; Yamasaki M
    J Control Release; 2002 Feb; 79(1-3):229-42. PubMed ID: 11853934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin.
    Kratz F; Ehling G; Kauffmann HM; Unger C
    Hum Exp Toxicol; 2007 Jan; 26(1):19-35. PubMed ID: 17334177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of potent monoclonal antibody auristatin conjugates for cancer therapy.
    Doronina SO; Toki BE; Torgov MY; Mendelsohn BA; Cerveny CG; Chace DF; DeBlanc RL; Gearing RP; Bovee TD; Siegall CB; Francisco JA; Wahl AF; Meyer DL; Senter PD
    Nat Biotechnol; 2003 Jul; 21(7):778-84. PubMed ID: 12778055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maleimidocysteineamido-DOTA derivatives: new reagents for radiometal chelate conjugation to antibody sulfhydryl groups undergo pH-dependent cleavage reactions.
    Lewis MR; Shively JE
    Bioconjug Chem; 1998; 9(1):72-86. PubMed ID: 9460549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats.
    Sjögren HO; Isaksson M; Willner D; Hellström I; Hellström KE; Trail PA
    Cancer Res; 1997 Oct; 57(20):4530-6. PubMed ID: 9377565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of cross-linking agents in determining the biochemical and pharmacokinetic properties of Mgr6-clavin immunotoxins.
    Dosio F; Arpicco S; Adobati E; Canevari S; Brusa P; De Santis R; Parente D; Pignanelli P; Negri DR; Colnaghi MI; Cattel L
    Bioconjug Chem; 1998; 9(3):372-81. PubMed ID: 9576812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.